ArticleEuropean archives of psychiatry and clinical neuroscience2011
Adrenergic α2A receptor gene is not associated with methylphenidate response in adults with ADHD.
Article in European archives of psychiatry and clinical neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies.Molecular psychiatry · 2016Pooled it
- Biological Predictors of Treatment Response in Adult Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review.Journal of personalized medicine · 2022Review
- Review and Meta-analysis on the Impact of theBiological psychiatry global open science · 2022Article
- Genetics in the ADHD Clinic: How Can Genetic Testing Support the Current Clinical Practice?Frontiers in psychology · 2022Review
- PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.Pharmacogenetics and genomics · 2019Review
- Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD.Molecular psychiatry · 2018Article
- Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder.Scientific reports · 2018Article
- A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study.Journal of neural transmission (Vienna, Austria : 1996) · 2016Article
- Genetic Variations in Attention Deficit Hyperactivity Disorder Subtypes and Treatment Resistant Cases.Psychiatry investigation · 2016Article
- Further evidence for the association between a polymorphism in the promoter region of SLC6A3/DAT1 and ADHD: findings from a sample of adults.European archives of psychiatry and clinical neuroscience · 2014Article
- Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.British journal of clinical pharmacology · 2014Review
- The role of a mineralocorticoid receptor gene functional polymorphism in the symptom dimensions of persistent ADHD.European archives of psychiatry and clinical neuroscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenergic α2A receptor gene (ADRA2A) is one of the most promising candidate genes for ADHD pharmacogenetics. Thus far, three studies have investigated the association between the ADRA2A -1291 C>G polymorphism and the therapeutic response to methylphenidate (MPH) in children with ADHD, all of them with positive results. The aim of this study is to investigate, for the first time, the association between three ADRA2A polymorphisms (-1291 C>G, -262 G>A, and 1780 C>T) and the response to MPH in adults with ADHD. The sample comprises 165 Brazilians of European descent evaluated in the adult ADHD outpatient clinic of the Hospital de Clínicas de Porto Alegre. The diagnostic procedures followed the DSM-IV criteria. Drug response was assessed by both categorical and dimensional approaches, through the scales Swanson, Nolan, and Pelham Rating scale version IV and the Clinical Global Impression-Severity Scale, applied at the beginning and after the 30th day of treatment. We found no evidence of association between the three ADRA2A polymorphisms and the therapeutic response to MPH treatment. Our findings do not support a significant role for the ADRA2A gene in ADHD pharmacogenetics, at least among adult patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.